GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Imunon Inc (FRA:CBO) » Definitions » Cyclically Adjusted Price-to-FCF

Imunon (FRA:CBO) Cyclically Adjusted Price-to-FCF : (As of Jun. 04, 2025)


View and export this data going back to 2012. Start your Free Trial

What is Imunon Cyclically Adjusted Price-to-FCF?

Shiller PE for Stocks: The True Measure of Stock Valuation


Imunon Cyclically Adjusted Price-to-FCF Historical Data

The historical data trend for Imunon's Cyclically Adjusted Price-to-FCF can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Imunon Cyclically Adjusted Price-to-FCF Chart

Imunon Annual Data
Trend Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24
Cyclically Adjusted Price-to-FCF
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Imunon Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Cyclically Adjusted Price-to-FCF Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Imunon's Cyclically Adjusted Price-to-FCF

For the Biotechnology subindustry, Imunon's Cyclically Adjusted Price-to-FCF, along with its competitors' market caps and Cyclically Adjusted Price-to-FCF data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Imunon's Cyclically Adjusted Price-to-FCF Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Imunon's Cyclically Adjusted Price-to-FCF distribution charts can be found below:

* The bar in red indicates where Imunon's Cyclically Adjusted Price-to-FCF falls into.


;
;

Imunon Cyclically Adjusted Price-to-FCF Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted Price-to-FCF takes the Free Cash Flow per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/FCF calculation. Because it considers this 10-year average, it's often referred to as the CAPFCF Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted Price-to-FCF.

Imunon's Cyclically Adjusted FCF per Share for the quarter that ended in Mar. 2025 is calculated as:

For example, Imunon's adjusted Free Cash Flow per Share data for the three months ended in Mar. 2025 was:

Adj_FreeCashFlowPerShare=Free Cash Flow per Share/CPI of Mar. 2025 (Change)*Current CPI (Mar. 2025)
=-0.197/134.9266*134.9266
=-0.197

Current CPI (Mar. 2025) = 134.9266.

Imunon Quarterly Data

Free Cash Flow per Share CPI Adj_FreeCashFlowPerShare
201506 -50.670 100.684 -67.903
201509 -43.527 100.392 -58.500
201512 -32.252 99.792 -43.607
201603 -38.559 100.470 -51.783
201606 -33.061 101.688 -43.868
201609 -31.669 101.861 -41.949
201612 -32.844 101.863 -43.505
201703 -26.550 102.862 -34.826
201706 -8.448 103.349 -11.029
201709 -7.980 104.136 -10.340
201712 -3.088 104.011 -4.006
201803 -3.222 105.290 -4.129
201806 -3.079 106.317 -3.908
201809 -3.083 106.507 -3.906
201812 4.420 105.998 5.626
201903 -3.946 107.251 -4.964
201906 -3.055 108.070 -3.814
201909 -2.864 108.329 -3.567
201912 -2.951 108.420 -3.672
202003 -2.622 108.902 -3.249
202006 -1.316 108.767 -1.633
202009 -1.481 109.815 -1.820
202012 -1.213 109.897 -1.489
202103 -2.376 111.754 -2.869
202106 -0.393 114.631 -0.463
202109 -0.566 115.734 -0.660
202112 -0.784 117.630 -0.899
202203 -1.264 121.301 -1.406
202206 -0.756 125.017 -0.816
202209 -0.668 125.227 -0.720
202212 -0.548 125.222 -0.590
202303 -0.456 127.348 -0.483
202306 -0.702 128.729 -0.736
202309 -0.471 129.860 -0.489
202312 -0.368 129.419 -0.384
202403 -0.576 131.776 -0.590
202406 -0.445 132.554 -0.453
202409 -0.253 133.029 -0.257
202412 -0.292 133.157 -0.296
202503 -0.197 134.927 -0.197

Add all the adjusted free cash flow per share together and divide 10 will get our Cyclically Adjusted FCF per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Imunon  (FRA:CBO) Cyclically Adjusted Price-to-FCF Explanation

Compared with the regular Price-to-Free-Cash-Flow, which works poorly for cyclical businesses, the Cyclically Adjusted Price-to-FCF smoothed out the fluctuations of free cash flow during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted Price-to-FCF should give similar results to regular Price-to-Free-Cash-Flow.


Imunon Cyclically Adjusted Price-to-FCF Related Terms

Thank you for viewing the detailed overview of Imunon's Cyclically Adjusted Price-to-FCF provided by GuruFocus.com. Please click on the following links to see related term pages.


Imunon Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Imunon Inc (FRA:CBO) » Definitions » Cyclically Adjusted Price-to-FCF
Traded in Other Exchanges
Address
997 Lenox Drive, Suite 100, Lawrenceville, NJ, USA, 08648
Imunon Inc is a clinical-stage biotechnology company focused on advancing a portfolio of treatments that harness the body's natural mechanisms to generate safe, effective, and durable responses across various human diseases, constituting a differentiating approach from conventional therapies. It is developing its non-viral DNA technology across its modalities. Its clinical program, IMNN-001, is a DNA-based immunotherapy for the localized treatment of ovarian cancer that has completed Phase II clinical studies. Additionally, the Company has entered a first-in-human study of its COVID-19 booster vaccine (IMNN-101).

Imunon Headlines

No Headlines